Genor goes one better
Can activity at CTLA-4 be added to PD-1 x VEGF blockade?
Another Roche TIGIT disappointment
Skyscraper-07 fails, while a Poseida-originated Car-T is also scrapped.
ASCO 2025 preview – late-breakers in focus
The curtain lifts on Veritac-2, rusfertide, and another double plenary for Astra.
Ivo combo beats Tevimbra, but can it beat Keytruda?
The PD-1 x VEGF molecule's latest win comes from Akeso's Harmoni-6 trial.
Lilly urges degrader caution
Meanwhile, the company plays down the risk of Jaypirca’s CLL approval being rescinded.
Trodelvy gets one up on Datroway in triple-negative breast
Gilead’s TROP2 ADC prevails in Ascent-04, in first-line PD-L1-positive TNBC.
RemeGen cools on DR5
A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
Bristol goes pivotal with SystImmune-partnered conjugate
The first global pivotal trial will be in first-line triple-negative breast cancer.
Mural hits a wall
The company scraps nemvaleukin after the latest failure, of Artistry-6.
Telix sees more backing for LAT1
TLX101 follows Ipax-1 with an apparent success in an academic trial.
